News about VHIO

A new treatment is effective for advanced HER2-low breast cancer

Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1

Clínic Barcelona

Research January 25 2022

The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.

Clínic Barcelona

Institutional September 18 2020

Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.